Video

Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Author(s):

Ruben Mesa, M.D.,Rami S. Komrokji, M.D.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a man with text.
Ojjaara helps patients with myelofibrosis by reducing spleen size, easing symptoms, and improving anemia to boost independence from blood transfusions.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
Related Content
Image of FDA offices
September 15th 2025

Rusfertide Earns Breakthrough Therapy Designation in Polycythemia Vera

Ryan Scott
Cancer Horizons podcast logo
September 15th 2025

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
A structured nurse-led clinic can help patients with myeloproliferative neoplasms: © stock.adobe.com.
September 15th 2025

Nurse-Led Clinics Bridge Gaps in Myeloproliferative Care

Bridget Hoyt
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
September 15th 2025

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
Long-term follow-up data from the phase 3 MANIFEST 2 clinical trial have been revealed: © stock.adobe.com
September 15th 2025

Pelabresib Plus Jakafi Elicits Meaningful Responses in Myelofibrosis

Alex Biese
Image of blood.
September 15th 2025

July Blood Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott